Nothing Special   »   [go: up one dir, main page]

BR112019005685A2 - células t com resistência à imunossupressão aumentada - Google Patents

células t com resistência à imunossupressão aumentada

Info

Publication number
BR112019005685A2
BR112019005685A2 BR112019005685A BR112019005685A BR112019005685A2 BR 112019005685 A2 BR112019005685 A2 BR 112019005685A2 BR 112019005685 A BR112019005685 A BR 112019005685A BR 112019005685 A BR112019005685 A BR 112019005685A BR 112019005685 A2 BR112019005685 A2 BR 112019005685A2
Authority
BR
Brazil
Prior art keywords
cells
resistance
modified
individual
increased immunosuppression
Prior art date
Application number
BR112019005685A
Other languages
English (en)
Inventor
Laugel Bruno
Skibbe Kathrin
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Publication of BR112019005685A2 publication Critical patent/BR112019005685A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

esta invenção se refere ao tratamento de câncer em um indivíduo pela administração de uma população de células t modificadas que expressam uma fosfodiesterase camp recombinante (pde) ou um fragmento da mesma e um receptor de antígeno que se liga especificamente às células de câncer no indivíduo. são fornecidas populações de células t modificadas e métodos de produção de populações de células t modificadas, juntamente com composições farmacêuticas e métodos de tratamento.
BR112019005685A 2016-09-23 2017-09-22 células t com resistência à imunossupressão aumentada BR112019005685A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1616238.0A GB201616238D0 (en) 2016-09-23 2016-09-23 Modified T cells
PCT/EP2017/074139 WO2018055140A1 (en) 2016-09-23 2017-09-22 T cells with increased immunosuppression resistance

Publications (1)

Publication Number Publication Date
BR112019005685A2 true BR112019005685A2 (pt) 2019-06-11

Family

ID=57539693

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005685A BR112019005685A2 (pt) 2016-09-23 2017-09-22 células t com resistência à imunossupressão aumentada

Country Status (13)

Country Link
US (2) US9976121B2 (pt)
EP (1) EP3516042A1 (pt)
JP (1) JP7269166B2 (pt)
KR (1) KR20200002775A (pt)
CN (1) CN110325633A (pt)
AU (1) AU2017330067B2 (pt)
BR (1) BR112019005685A2 (pt)
CA (1) CA3036309A1 (pt)
GB (1) GB201616238D0 (pt)
IL (1) IL265465A (pt)
MX (1) MX2019002998A (pt)
RU (1) RU2019112076A (pt)
WO (1) WO2018055140A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2891321T3 (es) 2016-04-08 2022-01-27 Adaptimmune Ltd Receptores de células T
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
GB201713078D0 (en) * 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
EP3784255A4 (en) * 2018-04-19 2022-06-22 Board of Regents, The University of Texas System MAGE-B2 SPECIFIC T LYMPHOCYTE RECEPTORS AND THEIR USES
CA3117539A1 (en) * 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
US20220152109A1 (en) 2019-03-18 2022-05-19 Ludwig Institute For Cancer Research Ltd A2/ny-eso-1 specific t cell receptors and uses thereof
JP2022542051A (ja) * 2019-07-23 2022-09-29 ウェン ヤン， 養子免疫療法のための組成物および方法
WO2021019472A1 (en) * 2019-07-30 2021-02-04 University Health Network T cell receptors and methods of use thereof
WO2021030153A2 (en) * 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
GB201911958D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of t cell production
WO2021229235A1 (en) * 2020-05-13 2021-11-18 Adaptimmune Limited Method of treatment of cancer or tumour
EP4149493A1 (en) * 2020-05-13 2023-03-22 Adaptimmune Limited Method of treatment of cancer or tumour
EP4374872A1 (en) * 2022-11-22 2024-05-29 Koninklijke Philips N.V. Pde enhanced car-t cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019767A1 (en) * 1992-04-07 1993-10-14 The Regents Of The University Of Michigan Cd28 pathway immunoregulation
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
PT658113E (pt) 1992-08-31 2005-03-31 Ludwig Inst Cancer Res Nonapeptideo isolado derivado do gene mage-3 e apresentado por hla-a1, e utilizacoes deste
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
KR100316209B1 (ko) 1994-03-01 2002-06-26 에드워드 에이. 맥더모 2세, 로이드 제이. 오울드 Mage유전자발현에의한암상태의결정
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
CN101935636A (zh) * 2002-11-09 2011-01-05 英美偌科有限公司 T细胞受体展示
GB0411123D0 (en) * 2004-05-19 2004-06-23 Avidex Ltd High-affinity NY-ESO T cell receptors
PT2856876T (pt) 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
EP2186825A1 (en) * 2008-11-13 2010-05-19 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Human-derived T cell receptors
US9937207B2 (en) * 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201417803D0 (en) 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells

Also Published As

Publication number Publication date
JP7269166B2 (ja) 2023-05-08
CA3036309A1 (en) 2018-03-29
JP2019528748A (ja) 2019-10-17
KR20200002775A (ko) 2020-01-08
US10689620B2 (en) 2020-06-23
US20180010095A1 (en) 2018-01-11
AU2017330067B2 (en) 2023-09-07
MX2019002998A (es) 2019-12-09
IL265465A (en) 2019-05-30
WO2018055140A1 (en) 2018-03-29
GB201616238D0 (en) 2016-11-09
EP3516042A1 (en) 2019-07-31
CN110325633A (zh) 2019-10-11
US20180298338A1 (en) 2018-10-18
AU2017330067A1 (en) 2019-04-18
RU2019112076A (ru) 2020-10-23
RU2019112076A3 (pt) 2021-06-09
US9976121B2 (en) 2018-05-22

Similar Documents

Publication Publication Date Title
BR112019005685A2 (pt) células t com resistência à imunossupressão aumentada
EA202092032A1 (ru) Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
BR112017000939A2 (pt) tratamento de câncer usando um receptor antigênico quimérico de cll-1
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
BR112017006710A2 (pt) vetor de expressão de car e células t expressando car
BR112016022912A2 (pt) molécula de ligação ao antígeno de imunoativação
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
BR112018005741A2 (pt) método de redirecionamento de células t para tratar infecção por hiv
BR112018071612A2 (pt) polipeptídeos biespecíficos inovadores contra cd137
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
BR112018003535A2 (pt) receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2016010998A (es) Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
BR112019011065A2 (pt) métodos para determinação da dosagem de células t car
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
BR112016020871A2 (pt) anticorpos anti-mcam e métodos associados de uso
PE20151871A1 (es) Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements